Metabolomics in chronic lung diseases

Shabarinath Nambiar, Sze Bong How, Joel Gummer, Robert Trengove, Yuben Moodley

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Chronic lung diseases represent a significant global burden. Their increasing incidence and complexity render a comprehensive, multidisciplinary and personalized approach to each patient, critically important. Most recently, unique biochemical pathways and disease markers have been identified through large-scale metabolomic studies. Metabolomics is the study of metabolic pathways and the measurement of unique biomolecules in a living system. Analysing samples from different compartments such as bronchoalveolar lavage fluid (BALF) and plasma has proven useful for the characterization of a number of pathological conditions and offers promise as a clinical tool. For example, several studies using mass spectrometry (MS) have shown alterations in the sphingolipid metabolism of chronic obstructive pulmonary disease (COPD) sufferers. In this article, we present a practical review of the application of metabolomics to the study of chronic lung diseases (CLD): COPD, idiopathic pulmonary fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in metabolomics, have provided to the dissection of the biochemistry of CLD and future clinical biomarkers are explored.

Original languageEnglish
Pages (from-to)139-148
JournalRespirology
Volume25
Issue number2
DOIs
Publication statusPublished - Feb 2020

Fingerprint

Metabolomics
Lung Diseases
Chronic Disease
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Sphingolipids
Bronchoalveolar Lavage Fluid
Metabolic Networks and Pathways
Biochemistry
Dissection
Mass Spectrometry
Asthma
Biomarkers
Incidence

Cite this

Nambiar, S., Bong How, S., Gummer, J., Trengove, R., & Moodley, Y. (2020). Metabolomics in chronic lung diseases. Respirology, 25(2), 139-148. https://doi.org/10.1111/resp.13530
Nambiar, Shabarinath ; Bong How, Sze ; Gummer, Joel ; Trengove, Robert ; Moodley, Yuben. / Metabolomics in chronic lung diseases. In: Respirology. 2020 ; Vol. 25, No. 2. pp. 139-148.
@article{835c71d06fe74646a8dc8f95433a2402,
title = "Metabolomics in chronic lung diseases",
abstract = "Chronic lung diseases represent a significant global burden. Their increasing incidence and complexity render a comprehensive, multidisciplinary and personalized approach to each patient, critically important. Most recently, unique biochemical pathways and disease markers have been identified through large-scale metabolomic studies. Metabolomics is the study of metabolic pathways and the measurement of unique biomolecules in a living system. Analysing samples from different compartments such as bronchoalveolar lavage fluid (BALF) and plasma has proven useful for the characterization of a number of pathological conditions and offers promise as a clinical tool. For example, several studies using mass spectrometry (MS) have shown alterations in the sphingolipid metabolism of chronic obstructive pulmonary disease (COPD) sufferers. In this article, we present a practical review of the application of metabolomics to the study of chronic lung diseases (CLD): COPD, idiopathic pulmonary fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in metabolomics, have provided to the dissection of the biochemistry of CLD and future clinical biomarkers are explored.",
keywords = "asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, lung, metabolomics",
author = "Shabarinath Nambiar and {Bong How}, Sze and Joel Gummer and Robert Trengove and Yuben Moodley",
year = "2020",
month = "2",
doi = "10.1111/resp.13530",
language = "English",
volume = "25",
pages = "139--148",
journal = "Asian Pacific Journal of Respirology",
issn = "1323-7799",
publisher = "John Wiley & Sons",
number = "2",

}

Nambiar, S, Bong How, S, Gummer, J, Trengove, R & Moodley, Y 2020, 'Metabolomics in chronic lung diseases' Respirology, vol. 25, no. 2, pp. 139-148. https://doi.org/10.1111/resp.13530

Metabolomics in chronic lung diseases. / Nambiar, Shabarinath; Bong How, Sze; Gummer, Joel; Trengove, Robert; Moodley, Yuben.

In: Respirology, Vol. 25, No. 2, 02.2020, p. 139-148.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Metabolomics in chronic lung diseases

AU - Nambiar, Shabarinath

AU - Bong How, Sze

AU - Gummer, Joel

AU - Trengove, Robert

AU - Moodley, Yuben

PY - 2020/2

Y1 - 2020/2

N2 - Chronic lung diseases represent a significant global burden. Their increasing incidence and complexity render a comprehensive, multidisciplinary and personalized approach to each patient, critically important. Most recently, unique biochemical pathways and disease markers have been identified through large-scale metabolomic studies. Metabolomics is the study of metabolic pathways and the measurement of unique biomolecules in a living system. Analysing samples from different compartments such as bronchoalveolar lavage fluid (BALF) and plasma has proven useful for the characterization of a number of pathological conditions and offers promise as a clinical tool. For example, several studies using mass spectrometry (MS) have shown alterations in the sphingolipid metabolism of chronic obstructive pulmonary disease (COPD) sufferers. In this article, we present a practical review of the application of metabolomics to the study of chronic lung diseases (CLD): COPD, idiopathic pulmonary fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in metabolomics, have provided to the dissection of the biochemistry of CLD and future clinical biomarkers are explored.

AB - Chronic lung diseases represent a significant global burden. Their increasing incidence and complexity render a comprehensive, multidisciplinary and personalized approach to each patient, critically important. Most recently, unique biochemical pathways and disease markers have been identified through large-scale metabolomic studies. Metabolomics is the study of metabolic pathways and the measurement of unique biomolecules in a living system. Analysing samples from different compartments such as bronchoalveolar lavage fluid (BALF) and plasma has proven useful for the characterization of a number of pathological conditions and offers promise as a clinical tool. For example, several studies using mass spectrometry (MS) have shown alterations in the sphingolipid metabolism of chronic obstructive pulmonary disease (COPD) sufferers. In this article, we present a practical review of the application of metabolomics to the study of chronic lung diseases (CLD): COPD, idiopathic pulmonary fibrosis (IPF) and asthma. The insights, which the analytical strategies employed in metabolomics, have provided to the dissection of the biochemistry of CLD and future clinical biomarkers are explored.

KW - asthma

KW - chronic obstructive pulmonary disease

KW - idiopathic pulmonary fibrosis

KW - lung

KW - metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85063377123&partnerID=8YFLogxK

U2 - 10.1111/resp.13530

DO - 10.1111/resp.13530

M3 - Review article

VL - 25

SP - 139

EP - 148

JO - Asian Pacific Journal of Respirology

JF - Asian Pacific Journal of Respirology

SN - 1323-7799

IS - 2

ER -

Nambiar S, Bong How S, Gummer J, Trengove R, Moodley Y. Metabolomics in chronic lung diseases. Respirology. 2020 Feb;25(2):139-148. https://doi.org/10.1111/resp.13530